Thompson N. Doman, Ph.D.
- Adjunct Professor, Bioinformatics
domantnlilly [dot] com
- Ph.D. Inorganic Chemistry, University of Louisville (1990)
- B.S. Chemistry, Computer Science, Western Kentucky University (1984)
After graduating with a doctorate in Inorganic Chemistry from the University of Louisville, Dr. Doman joined the laboratory of Brice Bosnich at the University of Chicago where he conducted postdoctoral
research in computational chemistry applied to inorganic systems. In 1992 he joined G.D. Searle (later Pharmacia Corporation) in Skokie, Ill. as a computational chemist. This period of time was a particularly strong growth period in the field of cheminformatics, and Doman developed numerous technologies at Searle for clustering, diversity analysis, and chemical library design. Most importantly he contributed to the discovery of the blockbuster drug Celebrex.
In 2003, Dr. Doman joined Eli Lilly & Company in Indianapolis as a Principal Research Scientist. Until 2010 he worked at Lilly to apply cheminformatics and computational chemistry techniques to drug discovery problems. Since then Dr. Doman has been involved in cancer research at Lilly, specifically focused on immuno-oncology, as a Research Advisor in the Oncology Genomics and Bioinformatics unit of Lilly Research Labs.
Research interests include tumorigenesis, immuno-oncology, aneuploidy, cancer treatment, computational biology methods, reproducible research. More generally, Dr. Doman is interested in improvement of communication through better uses of skills and technology in presentation and collaboration, coaching as a means of helping others realize their potential, and the crucial importance of improving critical thinking skills in society.